Switzerland and Korea are ideal innovation partners. Switzerland has excellent basic research and technologies and Korea is a world-leader in adapting and applying technologies quickly in order to move to market. In ICT, Korea has strong engineering and ICT technologies but Switzerland has better strengths in systemic thinking and adaptations as well including medical technologies in ICT. In biometical/medtech, Switzerland has the application power of Novartis and Roche. Meanwhile, Korean scientists and doctors are wokring on novel technologies.

Memorandum of Understanding

In 2013 and 2014, a number of agreements to promote bilateral cooperation in the area of innovation were signed between Swiss and Korean counterparts. These agreements also deal with applied research in private companies. Switzerland and South Korea are also working together in a public-private partnership – the Swiss-Korean Life Science Initiative – in the field of medical technology and biotechnology.

July 2013:

Swiss Commission for Technology and Innovation (CTI) and Korea Institute for the Advancement of Technology (KIAT) agreed a partnernship in innovation. Complementary knowledge and expertise in the two countries will be shared and applied in joint innovative projects.

January 2014:

MOU between State Secretariat for Education, Research and Innovation (SERI) and South Korean Ministry of Trade, Industry and Energy (MOTIE)

November 2014:

Declaration of Intent on Call for Proposal betwen KIAT, SERI and CTI was signed to jointly launch calls for science-based innovation projects in Switzerland and South Korea and to include funding oppotunities in all institutions.


The First Swiss-Korean Joint Call for R&D Innovation Projects specifically targets those who are to develop ready-to-market solutions or products. This first joint R&D Call was open to all industries for funding and applications closed on June 19th, 2015.

According to the conditions and eligibility criteria, there are three separate funding programs based on the different funding agencies:

  3. CTI-Bilateral project funding from South Korean research institutions

The funding criteria and financing options differ according to the funding instrument and institution. In individual cases, it may be possible to combine different funding options.The funding agencies can advise applicants on the basis of the project outline they submit.




A leading platform for R&D-performing entrepreneurs in Europe and beyond. EUREKA supports the enhancement of the industry competitiveness through R&D&I international collaborative projects. By having companies, research institutes and universities work together on transnational projects, it is possible to bring innovative products, processes and services to the market. Switzerland is a founding member of EUREKA and Korea has joined EUREKA as an associated member states since 2009.
So-called cluster and umbrella initiatives as well as the initiative Eurostars were built within the EUREKA network in order to respond more effectively to market needs. Clusters are long-term strategic industry initiatives, and umbrellas are thematically divided networks within EUREKA. Eurostars promotes cross-border projects from SMEs that conduct extensive research activities by providing them with grant funding.

The EUREKA Chairmanship is lead by Switzerland from July 2014 to June 2015.

For Swiss, please contact

For Korean, please contact

  • KIAT, Gitae Sim, Korea EUREKA project coordinator
  • Korea Institute for Advancement of Technology, KIAT
  • +82 2 6009 3182
Swiss-Korean Technology Cooperation Seminar

Swiss-Korean Technology Cooperation Seminar

The Swiss-Korean Technology Cooperation Seminar 2015 was organized by the Science and Technology Office of Embassy of Switzerland in Republic of Korea & KIAT.

  • The SERI representative, Andreas Gut, gave a brief presentation on Switzerland-Korea call for Joint R&D for Swiss and Korean innovators
  • Other presentations given by Swiss representatives:
    • Novartis Institutes for BioMedical Research (NIBR)
    • the Swiss IoT start-up Domo Safety
    • CSEM, a Swiss research institute focusing on ICT and microtechnology
    • The Vice-President of the Swiss Biotech Association, also leading the Commission for Technology and Innovation (CTI) biotech activities, introduced the Swiss national innovation agency
  • Other presentations given by Korean representatives:
    • Dongjin Semichem
    • KAIST

These presentations highlighted  innovation strengths and collaboration opportunities in four different fields of R&D – ICT, Clean-Tech, Internet of Things, Life Science.

Innovation Workshop Series

Innovation Workshop Series

The Science and Technology Office also inaugurated a new innovation workshop series in order to bring together mulch-disciplinary experts from Switzerland and Korea on the selected field of discussion for the workshop.

  • May 2015 – Neuroscience: Representatives from NIBR (Novartis), KAIST, Yonsei Severance Hospital, and Macrogen in the field of neuroscience (epilepsy) attended this workshop to further discuss how they can cooperate and find the best way to apply for the Joint R&D Call between Switzerland-Korea.
  • July 2015 – Oncology: For the second workshop, the attendees were from Novartis Korea and Ulsan National Institute of Science and Technology (UNIST). Researchers from UNIST presented their current research on developing new anti-cancer compounds focusing on “Mitochondria targeted Hsp90 Inhibitors.” Along with the introduction to the research, the attendees broadly discussed about global academic-industry R&D collaboration.

Like to talk to us?